Piper Sandler Maintains Overweight on Enfusion, Lowers Price Target to $12

Piper Sandler analyst Christopher Donat maintains Enfusion (NYSE:ENFN) with a Overweight and lowers the price target from $15 to $12.

Piper Sandler analyst Christopher Donat maintains Enfusion (NYSE:ENFN) with a Overweight and lowers the price target from $15 to $12.

Total
0
Shares
Related Posts
Read More

What’s Going On With AMC Shares?

AMC Entertainment Holdings Inc (NYSE: AMC) shares are trading lower by 1.53% to $4.83 Monday morning on continued downward momentum. The company last week announced an $85 million debt repayment. Shares could also be lower amid continued volatility in high-short interest stocks.

AMC